Protego
San Diego, US · 8 known investors
Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
Investors · 8
Droia VenturesLeuven · $540K
Novartis Venture FundBasel · $5M – $25M
Digitalis Venturesreported · 2 sourcesNew York · $100K – $10M
ForbionreportedNaarden
Lightspeed Venture PartnersreportedMenlo Park · $1.7M – $87M
MPM BioImpactreportedBoston · $1M – $15M
Vida VenturesreportedLos Angeles
YK BioventuresreportedBurlingame
Funding
SEC filings, press & company announcements- Undisclosed amountseries BDec 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlap
Synthego16 shared keywordsSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Protego for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Protego do?
- Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.
- Who are Protego's investors?
- Protego's investors include Droia Ventures, Novartis Venture Fund, Digitalis Ventures, Forbion, Lightspeed Venture Partners, MPM BioImpact, Vida Ventures, YK Bioventures.
- Where is Protego headquartered?
- Protego is headquartered in San Diego, US.